Amgen Inc. (LON:0R0T)

Market Cap	114.79B
Revenue (ttm)	25.49B
Net Income (ttm)	4.83B
Shares Out	n/a
EPS (ttm)	8.93
PE Ratio	23.76
Forward PE	14.10
Dividend	7.21 (2.53%)
Ex-Dividend Date	May 16, 2025

Volume	928
Average Volume	585
Open	286.01
Previous Close	285.58
Day's Range	282.79 - 286.57
52-Week Range	253.20 - 339.14
Beta	n/a
RSI	39.33
Earnings Date	Aug 4, 2025

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1980
• Employees: 28,000
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0R0T

Financial Performance

In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.

Financial numbers in USD